NO333614B1 - Farmasoytiske preparater av modafinil - Google Patents
Farmasoytiske preparater av modafinil Download PDFInfo
- Publication number
- NO333614B1 NO333614B1 NO20051079A NO20051079A NO333614B1 NO 333614 B1 NO333614 B1 NO 333614B1 NO 20051079 A NO20051079 A NO 20051079A NO 20051079 A NO20051079 A NO 20051079A NO 333614 B1 NO333614 B1 NO 333614B1
- Authority
- NO
- Norway
- Prior art keywords
- modafinil
- approx
- unit dose
- dose according
- dose
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 185
- 229960001165 modafinil Drugs 0.000 title claims abstract description 175
- 239000000825 pharmaceutical preparation Substances 0.000 title description 11
- 239000011230 binding agent Substances 0.000 claims abstract description 12
- 239000000314 lubricant Substances 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 11
- 239000007884 disintegrant Substances 0.000 claims abstract description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 29
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 10
- 229960001021 lactose monohydrate Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 9
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 4
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000391 magnesium silicate Substances 0.000 claims description 4
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 4
- 235000019792 magnesium silicate Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 35
- 239000000654 additive Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 229920003084 Avicel® PH-102 Polymers 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
- 229920003082 Povidone K 90 Polymers 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005422 blasting Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940117394 provigil Drugs 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- -1 hypnosis Chemical compound 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042635 Suspiciousness Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41039502P | 2002-09-13 | 2002-09-13 | |
| US10/660,058 US20040116532A1 (en) | 2002-09-13 | 2003-09-11 | Pharmaceutical formulations of modafinil |
| PCT/US2003/028651 WO2004024134A1 (en) | 2002-09-13 | 2003-09-12 | Pharmaceutical formulations of modafinil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051079L NO20051079L (no) | 2005-03-23 |
| NO333614B1 true NO333614B1 (no) | 2013-07-22 |
Family
ID=32511269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051079A NO333614B1 (no) | 2002-09-13 | 2005-02-28 | Farmasoytiske preparater av modafinil |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20040116532A1 (is) |
| EP (1) | EP1539126B1 (is) |
| JP (1) | JP5039246B2 (is) |
| KR (1) | KR101125462B1 (is) |
| CN (1) | CN100528151C (is) |
| AU (1) | AU2003267156B2 (is) |
| BR (1) | BR0314514A (is) |
| CA (1) | CA2498260C (is) |
| DK (1) | DK1539126T3 (is) |
| EA (1) | EA012964B1 (is) |
| ES (1) | ES2392580T3 (is) |
| HK (1) | HK1076734A1 (is) |
| IL (1) | IL167054A (is) |
| IS (1) | IS2871B (is) |
| MX (1) | MXPA05002827A (is) |
| NO (1) | NO333614B1 (is) |
| NZ (1) | NZ538941A (is) |
| PL (1) | PL375833A1 (is) |
| PT (1) | PT1539126E (is) |
| SI (1) | SI1539126T1 (is) |
| TW (1) | TWI335217B (is) |
| WO (1) | WO2004024134A1 (is) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ524359A (en) | 2000-07-27 | 2005-06-24 | Teva Pharma | Crystalline and pure modafinil, and process of preparing the same |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20070066996A1 (en) * | 2003-03-17 | 2007-03-22 | Katzman Daniel E | Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR046410A1 (es) * | 2003-09-18 | 2005-12-07 | Cephalon Inc | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
| UA94380C2 (ru) * | 2003-09-18 | 2011-05-10 | Сефалон, Інк. | Фармацевтические композиции модафинила с модифицированным высвобождением |
| WO2005099822A2 (en) * | 2004-04-13 | 2005-10-27 | Cephalon, Inc. | Reduction of drug / drug interactions with modafinil |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| NZ551340A (en) * | 2004-04-22 | 2010-10-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder |
| US20060024370A1 (en) | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| BRPI0500520A (pt) * | 2005-02-16 | 2006-09-26 | Henry Jun Suzuki | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1904182A2 (en) * | 2005-05-06 | 2008-04-02 | Boehringer Ingelheim International GmbH | Method for the treatment of drug abuse with flibanserin |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| WO2006125042A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| JP2009513604A (ja) * | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| EP1988898A2 (en) * | 2006-02-18 | 2008-11-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| JP5793828B2 (ja) * | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| EP2056797A2 (en) * | 2006-08-25 | 2009-05-13 | Boehringer Ingelheim International GmbH | Controlled release system and method for manufacturing the same |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
| UY31335A1 (es) * | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| FR2987265B1 (fr) * | 2012-02-28 | 2014-02-28 | Debregeas Et Associes Pharma | Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1570994A (en) | 1923-11-20 | 1926-01-26 | William A Cook | Spring-forming die |
| US3629393A (en) | 1969-09-11 | 1971-12-21 | Nikken Chemicals Co Ltd | Release-sustaining-tablet |
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| DE2927988A1 (de) | 1979-07-11 | 1981-02-05 | Thomae Gmbh Dr K | Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel |
| US4431645A (en) | 1982-03-08 | 1984-02-14 | Schering Corporation | Antihypertensive agents |
| HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
| US4584285A (en) | 1983-06-02 | 1986-04-22 | Schering Corporation | Antihypertensive agents |
| US4710519A (en) | 1985-09-30 | 1987-12-01 | Basf Corporation | Process for preparing spray dried acetaminophen powder and the powder prepared thereby |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| US5084277A (en) | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| GB9225492D0 (en) | 1992-12-05 | 1993-01-27 | Glaxo Group Ltd | Amine derivatives |
| TW272942B (is) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
| US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| FR2702968B1 (fr) | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
| FR2706767B1 (is) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2707637B1 (fr) * | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5506248A (en) | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| AU722304B2 (en) * | 1996-01-19 | 2000-07-27 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| JPH09208468A (ja) * | 1996-02-02 | 1997-08-12 | Dainippon Pharmaceut Co Ltd | ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤 |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| CA2271865C (en) | 1996-11-15 | 2003-10-14 | Ajinomoto Co., Inc. | Tablet composition |
| GB9714274D0 (en) | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
| EP1017370B1 (en) | 1997-09-11 | 2003-10-29 | Nycomed Danmark ApS | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| IL143407A0 (en) | 1998-12-18 | 2002-04-21 | Abbott Lab | Controlled release formulation of divalproex sodium |
| HUP0104606A3 (en) * | 1998-12-18 | 2003-01-28 | Basf Ag | A pharmaceutical mixture comprising a profen |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
| US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| IL155322A0 (en) | 2000-10-11 | 2003-11-23 | Cephalon Inc | Compositions comprising modafinil compounds |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| PT1330244E (pt) * | 2000-10-11 | 2009-01-27 | Cephalon Inc | Composições compreendendo compostos de modafinil |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| ES2281527T3 (es) | 2001-05-25 | 2007-10-01 | Cephalon, Inc. | Formulaciones farmaceuticas solidas que comprenden modafinilo. |
| US7576133B2 (en) * | 2002-03-11 | 2009-08-18 | Carl Henry Lawyer | Methods and compositions for nasal administration of modafinil |
| US7229644B2 (en) | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| WO2004004692A1 (en) | 2002-07-08 | 2004-01-15 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
| WO2004010979A1 (en) | 2002-07-25 | 2004-02-05 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
-
2003
- 2003-09-11 US US10/660,058 patent/US20040116532A1/en not_active Abandoned
- 2003-09-12 EP EP03749630A patent/EP1539126B1/en not_active Expired - Lifetime
- 2003-09-12 CN CNB03821749XA patent/CN100528151C/zh not_active Expired - Fee Related
- 2003-09-12 DK DK03749630.4T patent/DK1539126T3/da active
- 2003-09-12 PT PT03749630T patent/PT1539126E/pt unknown
- 2003-09-12 CA CA2498260A patent/CA2498260C/en not_active Expired - Fee Related
- 2003-09-12 ES ES03749630T patent/ES2392580T3/es not_active Expired - Lifetime
- 2003-09-12 KR KR1020057004198A patent/KR101125462B1/ko not_active IP Right Cessation
- 2003-09-12 MX MXPA05002827A patent/MXPA05002827A/es active IP Right Grant
- 2003-09-12 JP JP2004536184A patent/JP5039246B2/ja not_active Expired - Fee Related
- 2003-09-12 BR BR0314514-0A patent/BR0314514A/pt not_active IP Right Cessation
- 2003-09-12 NZ NZ538941A patent/NZ538941A/en not_active IP Right Cessation
- 2003-09-12 PL PL03375833A patent/PL375833A1/xx not_active Application Discontinuation
- 2003-09-12 WO PCT/US2003/028651 patent/WO2004024134A1/en active Application Filing
- 2003-09-12 SI SI200332193T patent/SI1539126T1/sl unknown
- 2003-09-12 AU AU2003267156A patent/AU2003267156B2/en not_active Ceased
- 2003-09-12 EA EA200500488A patent/EA012964B1/ru not_active IP Right Cessation
- 2003-09-15 TW TW092125314A patent/TWI335217B/zh not_active IP Right Cessation
-
2005
- 2005-02-22 IL IL167054A patent/IL167054A/en not_active IP Right Cessation
- 2005-02-24 IS IS7714A patent/IS2871B/is unknown
- 2005-02-28 NO NO20051079A patent/NO333614B1/no not_active IP Right Cessation
- 2005-10-04 HK HK05108798.2A patent/HK1076734A1/xx not_active IP Right Cessation
-
2008
- 2008-04-24 US US12/150,056 patent/US8268892B2/en not_active Expired - Fee Related
-
2012
- 2012-08-21 US US13/590,912 patent/US8859621B2/en not_active Expired - Fee Related
- 2012-08-21 US US13/590,865 patent/US8686047B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333614B1 (no) | Farmasoytiske preparater av modafinil | |
| Starkstein et al. | Apathy and depression following stroke | |
| JP2001510800A (ja) | 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| TW201601715A (zh) | 膀胱‧尿道協同失調改善劑 | |
| JP6042886B2 (ja) | 早漏症治療用の薬学組成物 | |
| JP2593910B2 (ja) | パニック障害の予防又は抑制剤 | |
| ZA200502789B (en) | Pharmaceutical formulations of modafinil | |
| ULC | PrMYLAN-ELETRIPTAN | |
| CA2822213A1 (en) | Combination and composition for treating obesity | |
| Dom-SERTRALINE | DOMINION PHARMACAL | |
| CA2990396A1 (en) | Combination medication for neuro-degenerative diseases | |
| Wyeth | PrEFFEXOR® XR | |
| ULC | PrMYLAN-SERTRALINE | |
| WO2023272335A1 (en) | Cannabidiol formulation comprising a matrix pellet forming excipient | |
| Wyeth | Pr EFFEXOR® XR Capsules | |
| EP4373492A1 (en) | Hydroxychloroquine formulations, dosage forms, and methods of use | |
| Tablets et al. | H9R 4Z7 | |
| MX2008004863A (es) | Métodos de tratamiento de desordenes del sistema nervioso central con una combinación de dosis baja de escitalopram y bupropion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |